使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Good morning. My name is Tamara and I will be conference facilitator today. At this time I would like to welcome everyone to the ICN first quarter 2003 earnings conference call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks there will be a question and answer period. Please limit yourself to one question at a time to allow all participants an opportunity to ask questions. As a reminder, this call is being recorded.
早安。我叫 Tamara,今天將擔任本次電話會議的主持人。此刻我謹代表 ICN,歡迎各位參加 2003 年第一季財報電話會議。為避免任何背景雜音,所有線路均已設為靜音。在講者發言結束後,將進行問答時間。為讓所有與會者都有機會提問,請每次僅提出一個問題。提醒各位,本次電話會議將被錄音。
At this time, for opening remarks and introductions, I would now like to turn the conference over to Mr. Gregg Keever, executive vice president, general counsel, and corporate secretary of ICN. Please go ahead, sir.
現在進行開場致詞與介紹,我想把電話會議交給 ICN 的執行副總裁、總法律顧問兼公司秘書 Gregg Keever 先生。先生,請開始。
Gregory Keever - Executive VP, General Counsel and Secretary
Gregory Keever - Executive VP, General Counsel and Secretary
Thank you: good morning and welcome to today's call.
謝謝:早安,歡迎各位參加今天的電話會議。
Before we begin the call, I would like to read to you the following statement. This presentation contains forward-looking statements that involve risks and uncertainties, including but not limited to projections of future sales, royalty income, operating income, return on invested assets, regulatory approval processes, competition from generic products, marketplace acceptance of the company's products, success of the company's strategic repositioning initiatives, and the ability of management to execute them, cost cutting measures and other risks details detailed from time to time in the company's Securities and Exchange Commission filings.
在我們開始之前,我想向各位宣讀以下聲明。本簡報包含前瞻性陳述,涉及風險與不確定性,包括但不限於對未來銷售、權利金收入、營業利益、投入資產報酬、法規核准流程、學名藥競爭、公司產品的市場接受度、公司策略性重新定位計畫的成功與管理階層執行能力、成本削減措施,以及其他風險;相關細節將不時載於公司向美國證券交易委員會(SEC)提交的文件中。
Joining us on the call today are Robert O'Leary, ICN's chairman and chief executive officer, Timothy Tyson, president and chief operating office, Bary Bailey, chief financial officer, Wes Wheeler, president of North America, Whinny Wiu (ph) controller and Phil Loberg (ph), treasure.
今天與我們一同參與電話會議的有:ICN 董事長兼執行長 Robert O'Leary、總裁兼營運長 Timothy Tyson、財務長 Bary Bailey、北美區總裁 Wes Wheeler、控制長 Whinny Wiu(音),以及財務主管 Phil Loberg(音)。
And now I'd like to turn the call over to Rob O'Leary.
現在我想把電話會議交給 Rob O'Leary。
Robert W. O'Leary - Chairman and CEO
Robert W. O'Leary - Chairman and CEO
Thank you, Gregg. And thank you, everyone, for joining us this morning.
謝謝你,Gregg。也謝謝各位今天早上加入我們。
As we told you last quarter, our first quarter comparisons to the previous year would be difficult. Primarily due to our successful efforts to reduce the level of inventory at wholesalers in North America. We also told you that we expected those efforts to continue through the first half of this year. Today, however, the timing of the outcome of these efforts is no longer in doubt. I am happy to report that as of today's call, we have completed our inventory reduction measures to four months ahead of schedule. And just as important, despite the impact on sales of our inventory reduction program, our North American region delivered good product performance.
正如我們上季告訴各位的,我們第一季與去年同期的比較會很艱難。主要原因在於我們成功降低北美批發商的庫存水位。我們也告訴各位,我們預期這些努力會持續到今年上半年。然而今天,這些努力成果出現的時間點已不再有疑問。我很高興報告,截至今天這通電話會議,我們已提前四個月完成庫存削減措施。同樣重要的是,儘管庫存削減計畫對銷售造成影響,我們北美區仍展現良好的產品表現。
We've invited Wes Wheeler, a our new president of North American operations, to talk about what's going on in North American -- North America a little later. Tim and Bary were will provide an overview of our worldwide business after that.
我們邀請了 Wes Wheeler——我們新任北美營運總裁——稍後談談北美的最新情況。之後 Tim 與 Bary 將提供我們全球業務的概覽。
I'm also pleased to report that we continue to deliver on the execution of our strategic redirection in the quarter. We are beginning to see tangible results from these efforts as we lay a foundation for greater accomplishments later this year and in 2004.Our new management team, which is now substantially complete, has been active in implementing a series of substantive initiatives to improve operational efficiency and to drive future growth.
我也很高興報告,我們在本季持續落實策略轉向的執行。隨著我們為今年稍晚及 2004 年更大的成果奠定基礎,我們開始看到這些努力帶來的具體成效。我們的新管理團隊目前已大致到位,並積極推動一系列實質性措施,以提升營運效率並帶動未來成長。
We have begun the first phase of our multiphase procurement initiative to leverage our international buying power. Tim will provide more details why we are confident this program will have a significant impact. Some of which we now believe will impact the current fiscal year. We've also taken the first steps in our manufacturing rationalization process by identifying initial targets and formulating plans for significant changes. Our proposal will be completed by the end of the year. And we will be implementing the plan over the next few years. ICN is quickly moving through its strategic repositioning and transforming itself into an operationally focused company.
我們已啟動多階段採購計畫的第一階段,以運用我們的國際採購規模。Tim 將進一步說明我們為何有信心此計畫將帶來顯著影響。其中部分效益我們目前認為將影響本會計年度。我們也已在製造合理化流程上邁出第一步,辨識初步目標並擬定重大變革計畫。我們的提案將於年底前完成。並將在未來幾年內逐步推動該計畫。ICN 正快速推進其策略性重新定位,並轉型為以營運為核心的公司。
Through targeted toss savings, manufacturing and supply chain efficiencies, and procurement initiatives, ICN is improving its business by operating in smarter, more productive ways. We continue to believe that 2003 is a year of focus for the company and one in which we will continue to see benefits from our strategic repositioning efforts,.
透過有針對性的成本節省、製造與供應鏈效率提升,以及採購計畫,ICN 正以更聰明、更高生產力的方式營運,進而改善業務表現。我們仍然相信 2003 年是公司聚焦的一年,並且我們將持續看到策略性重新定位努力所帶來的效益。
With a challenging first quarter behind us and frankly more accomplished than we had expected, particularly in the U.S., our most significant market opportunity, we expect a second and third quarters to show steady improvement and the fourth quarter to reflect a strong and positive effects of our initiatives. We have also made excellent process progress on our divestiture program which I will elaborate on later.
在充滿挑戰的第一季過後,坦白說,我們的達成情況超出原先預期,尤其是在美國——我們最重要的市場機會——我們預期第二季與第三季將呈現穩健改善,而第四季將反映我們各項措施帶來的強勁且正面的效果。我們在資產剝離計畫方面也取得極佳的流程進展,稍後我會再進一步說明。
But now, I'd like to turn the call over to Tim Tyson, our president, who will chair share more of the operational improvements we've implemented throughout the organization. Tim.
不過現在,我想把電話會議交給我們的總裁 Tim Tyson,由他分享我們在整個組織中已實施的更多營運改善。Tim。
Timothy C. Tyson - President and COO
Timothy C. Tyson - President and COO
Thank you, Rob. And good morning, everyone.
謝謝你,Rob。各位早安。
As Rob indicated, the first quarter was focussed on taking the additional steps necessary to realign our business and making tangible progress in our repositioning efforts. Last quarter, we discussed cost-cost-cutting measures we are implementing and the long-term objectives we have for reducing SG & A, cost of goods sold, and more. While our immediate focus is to stop spending money where it does not add value and to invest in areas that drive growth in our business, the future success of our business is investing in activities that will drive the top line and in implementing an innovation strategy that will bring new products to market. These efforts are well under way.
如 Rob 所指出,第一季的重點在於採取必要的額外步驟,以重新調整我們的業務,並在重新定位的努力上取得具體進展。上季我們討論了正在推動的成本削減措施,以及我們在降低銷售、一般及行政費用(SG&A)、銷貨成本等方面的長期目標。雖然我們眼前的重點是停止在不增加價值之處花錢,並投資於能推動業務成長的領域,但我們未來的成功在於投資能帶動營收的活動,並落實創新策略,把新產品推向市場。這些工作已在積極進行中。
As Rob mentioned, we are complementing the first face of a multiphase procurement plan which will help us centralize our global purchasing activities and leverage our international buying power. As a matter of fact, we have already taken action which will generate millions of dollars of savings and we expect to deliver benefits by the end of 2003.
如 Rob 所提到,我們正在完成多階段採購計畫的第一階段,這將協助我們集中全球採購活動並運用國際採購規模。事實上,我們已採取行動,將帶來數百萬美元的節省,並預期在 2003 年底前實現效益。
Our second significant initiative is our manufacturing rationalization plan. We have begun our manufacturing rationalization efforts and will develop an integrated plan by the third quarter of this year. This plan focuses on improving our current average capacity utilization of 5-15% in our 31 manufacturing sites. By reducing the number of manufacturing facilities, increasing the productivity of our manufacturing operations, and rationalizing our third-party suppliers to reduce the cost of materials, this program will be implemented over a number of years and we expect to see a reduction in the cost of goods sold over time. As the manufacturing plan is completed, we will share it with you.
我們第二項重大措施是製造合理化計畫。我們已開始推動製造合理化工作,並將在今年第三季前制定一套整合計畫。該計畫聚焦於改善我們在 31 個製造據點目前平均 5% 至 15% 的產能利用率。透過減少製造設施數量、提升製造營運生產力,以及合理化第三方供應商以降低材料成本,此計畫將在數年內逐步實施,我們預期銷貨成本將隨時間下降。待製造計畫完成後,我們將與各位分享。
To drive the top line, we are aggressively pursuing opportunities to expand our product portfolio through internal discoveries and strategic acquisition. As well as identify strategic products and market them globally. During the quarter, our regions turned in strong product performance with some difficulty experienced in Latin America. In Europe, we experienced a 24.1% increase in sales from year ago results. These results were driven by growth in Mestinon, Calsitonin (ph) Virazole, and Guvin (ph) .
為推動營收成長,我們正積極尋求機會,透過內部研發成果與策略性併購來擴充產品組合。同時也辨識策略性產品並在全球進行行銷。本季各區域繳出強勁的產品表現,但拉丁美洲遇到一些困難。在歐洲,我們的銷售較去年同期成長 24.1%。這些成果主要由 Mestinon、Calsitonin(音)、Virazole 與 Guvin(音)的成長所帶動。
Our AAA business, Africa, Australia and Asia grew by 8% driven by Virazole and Reptilase (ph). We have implemented a number of steps to grow our European business, including launching line extensions, enhancing the product life cycles through medical studies, increasing the number of sales representatives, and improving their performance-performance-based incentive. We have removed the distraction created by the former international headquarters and have given management in Europe new leadership direction that has greatly improved their focus and execution.
我們的 AAA 業務(非洲、澳洲及亞洲)成長 8%,主要由 Virazole 與 Reptilase(ph)帶動。我們已採取多項措施以擴大歐洲業務,包括推出產品線延伸、透過醫學研究強化產品生命週期、增加業務代表人數,並改善其以績效為基礎的獎酬機制。我們已排除前國際總部所造成的干擾,並為歐洲管理團隊提供新的領導方向,顯著提升其專注度與執行力。
Sales for Latin America were down from last year's results due to continued economic pressures in the region. Volume of Bedoyecta in Mexico but positive results in the country were masked by negative foreign currency translation.
拉丁美洲的銷售較去年下滑,原因是該地區持續承受經濟壓力。墨西哥 Bedoyecta 的銷量以及該國的正面成果,因不利的外幣換算而被掩蓋。
Overall sales in North America, compared to the prior year were down significantly due to our continuing and successful effort to reduce wholesale inventory levels. These efforts reduced sales in the current quarter. But they have paid off with a completion of our efforts two months ahead of schedule. Our core U.S. products, namely he Efudex, Kinerlase, Glyquin continued to enjoy strong prescription demand.
北美整體銷售與前一年相比大幅下降,主要因我們持續且成功地降低批發通路庫存水位。這些措施使本季銷售下滑。但其成效顯著,我們比原定時程提前兩個月完成相關工作。我們美國核心產品(包括 Efudex、Kinerlase、Glyquin)持續享有強勁的處方需求。
And now I'd like to turn the call over to Wes Wheeler our new president of North American operation and head of global marketing to discuss some results for the market that is the primary focus of our strategic repositioning efforts and which represents our most significant future opportunity. Wes?
接下來我想把電話交給 Wes Wheeler——我們新任北美營運總裁暨全球行銷主管——來討論這個市場的一些成果;該市場是我們策略重新定位工作的主要焦點,也代表我們未來最重要的機會。Wes?
Wes Wheeler - President of North America
Wes Wheeler - President of North America
Thank you, Tim.
謝謝你,Tim。
In the short time that I've been here, I've already seen improvements in North American operations. I'm pleased to be part of the team that successfully completed our wholesale inventory reduction two months ahead schedule. As part of this program we now maintain an active dialog with the three primary pharmaceutical wholesalers and have worked with these wholesalers to deliver on our promise to successfully reduce our inventory levels. We continue to work with them to track the inventory of all of our products at SKU level.
在我到任的短時間內,我已經看到北美營運的改善。我很高興能成為團隊的一員,並成功在原定時程前兩個月完成批發通路庫存削減。作為此計畫的一部分,我們現在與三大主要藥品批發商保持積極對話,並與其合作以兌現我們成功降低庫存水位的承諾。我們也持續與他們合作,在 SKU 層級追蹤我們所有產品的庫存。
Going forward we expect to see ICN's sales to wholesalers more closely reflect the retail demand. In addition to completing our wholesale -- our inventory reduction program, we have continued to see strong performance from our core products. Our flagship product Efudex, continues to perform well. In the first quarter of 2003, based on INS data we maintained our market leading position with a 51.2% market share at expense of competing products. It is clear the that the impact of realigning and retraining our sales force and updating our marketing messages have paid off. We are working on new marketing and sales tactics to further enhance Efudex performance.
展望未來,我們預期 ICN 對批發商的銷售將更貼近零售端需求。除了完成批發——庫存削減計畫之外,我們核心產品的表現仍然強勁。我們的旗艦產品 Efudex 持續表現良好。根據 INS 數據,2003 年第一季我們維持市場領先地位,市占率達 51.2%,並以競品為代價取得成長。很明顯,重新調整並再訓練業務團隊,以及更新行銷訊息所帶來的效果已經顯現。我們正在制定新的行銷與銷售策略,以進一步提升 Efudex 的表現。
Our second promoted dermatology product Glyquin continues to perform well in a competitive market. Last year ICN lost significant market share to other products. We've been able to stop the market share loss by introducing our own line extension Glyquin XM. Launched only last October Glyquin XM has only achieved 6% market share. This new line extension coupled with a newly incentivised (ph) sales force has allowed ICN maintain its position in this highly competitive marketplace.
我們第二個主打的皮膚科產品 Glyquin 在競爭激烈的市場中仍持續表現良好。去年 ICN 的市占率曾大幅流失給其他產品。我們透過推出自有的產品線延伸 Glyquin XM,已成功阻止市占下滑。Glyquin XM 於去年 10 月才上市,目前已取得 6% 的市占率。此一新產品線延伸,加上重新設計激勵制度(ph)的業務團隊,使 ICN 得以在高度競爭的市場中維持其地位。
Mestinon sales in the quarter declined due to a generic product launch this year. But the decline was less than expected. Statistical modeling as market share patterns for products in a post-generic marketplace would yield an expectation for market shares for Mestinon at 68%.Yet according to IMS data Mestinon's market share was 78% in March providing stronger sales performance for ICN than expected.
本季 Mestinon 銷售下滑,原因是今年有學名藥上市。但下滑幅度低於預期。依據對學名藥上市後市場中產品市占型態的統計模型,Mestinon 的預期市占率應為 68%。然而根據 IMS 數據,Mestinon 在 3 月的市占率為 78%,使 ICN 的銷售表現優於預期。
Kinerase is our casmasutical (ph) product sold through physicians' offices. In North America, our renewed sales efforts and creative marketing tactics enabled us to achieve significant increase in sales as compared to the last quarter and the first quarter of the prior year. We are planning to launch two important line extensions this summer which we expect will drive further growth in this lucrative market.
Kinerase 是我們的醫美(ph)產品,透過醫師診所通路銷售。在北美,我們重新投入的銷售努力與創新的行銷策略,使我們相較上一季以及去年同期第一季的銷售均大幅成長。我們計畫在今年夏天推出兩項重要的產品線延伸,預期將帶動這個高獲利市場的進一步成長。
With the first quarter behind us we are very optimistic about the opportunities that lie ahead. And with that I'd like to turn the call to Bary Bailey for a discussion of our first quarter financial results. Bary.
第一季已經結束,我們對未來的機會感到非常樂觀。接下來我想把電話交給 Bary Bailey,請他說明我們第一季的財務結果。Bary。
Bary G. Bailey - Executive VP, CFO
Bary G. Bailey - Executive VP, CFO
Thank you, Wes. And thank you, everyone, for joining us again.
謝謝你,Wes。也謝謝各位再次加入我們。
Now let's get started with the financial review. Revenues from continuing operation from the first quarter of 2003 were 158.7 million compared to revenues of 185 million in the same period last year or down 14%.We reported net income for the quarter of 13.7 million or 16 cents per diluted share compared to net income of 8.4 million or 10 cents per diluted share in the same period last year.
現在我們開始進行財務回顧。2003 年第一季持續營運的營收為 1.587 億美元,去年同期為 1.85 億美元,下降 14%。我們本季淨利為 1,370 萬美元,稀釋後每股盈餘 0.16 美元;去年同期淨利為 840 萬美元,稀釋後每股盈餘 0.10 美元。
Income from continuing operations in the first quarter was 13.2 million or 16 cents per diluted share versus 31.1 million or 37 cents per diluted share last year. Operating income was 32.4 million in the first quarter versus 64.7 million a year ago.
第一季持續營運所得為 1,320 萬美元,稀釋後每股盈餘 0.16 美元;去年同期為 3,110 萬美元,稀釋後每股盈餘 0.37 美元。第一季營業利益為 3,240 萬美元,去年同期為 6,470 萬美元。
Overall, our gross margin in the first quarter was down almost 9 percentage points from the same period in the prior year. Including North America, where we expected a decline in gross margin as a result of our efforts to reduce wholesaler inventory, gross margin in the rest of the world was at 62.4% compared with 64.5% in 2002.
整體而言,我們第一季的毛利率較前一年同期下滑將近 9 個百分點。包含北美在內(我們原本就預期因降低批發商庫存而使毛利率下滑),世界其他地區的毛利率為 62.4%,相較 2002 年的 64.5% 略低。
Income from discontinued operations in the first quarter was 449,000 compared to a loss of $956,000 in 2002. As I mentioned last quarter, we expected the first quarter to be challenging.
第一季停業部門所得為 44.9 萬美元,相較 2002 年為虧損 95.6 萬美元。如我在上季所提到,我們預期第一季將充滿挑戰。
Ribapharm royalties revenue declined 14.8% in the first quarter to 48.6 million compared to 57 million in the first quarter last year. As you know Ribapharm royalty revenues are derived from sales by Ribapharm by sharing Plough and Roche to wholesalers which experienced a decline in sales in the first quarter.
Ribapharm 權利金收入第一季下滑 14.8% 至 4,860 萬美元,去年同期為 5,700 萬美元。如各位所知,Ribapharm 權利金收入來自 Ribapharm 由 Schering Plough 與 Roche 對批發商的銷售分成;而該等銷售在第一季出現下滑。
As we discussed with you last quarter, we anticipated that the royalty revenues in the 2002 fourth quarter were not sustainable as Schering (ph) increased it's sales and marketing efforts ahead of Roche's entry into the market.
如同我們上季與各位討論的,我們預期 2002 年第四季的權利金收入並不可持續,因為 Schering(ph)在 Roche 進入市場之前加大了其銷售與行銷投入。
ICN's focus remains on the specialty pharmaceuticals business. Revenues were strong in Europe bolstered by a strong Euro but this growth was offset by a decrease in revenues in North America primarily due to the impact of our successful wholesale inventory reduction program and weakness in Latin America. Latin America was negatively impacted, as mentioned before, by foreign currency translation.
ICN 的重點仍放在專科製藥業務。歐洲營收表現強勁,受惠於歐元走強,但此成長被北美營收下滑所抵銷;北美下滑主要是我們成功的批發通路庫存削減計畫所致,另加上拉丁美洲疲弱。如前所述,拉丁美洲亦受到外幣換算的不利影響。
In the first quarter North American revenues declined by 26.6 million or 63.3% under the same period in the previous year. The decline in sales primarily reflects the impact of the company's inventory status and the program to reduce inventory at U.S. wholesalers. To reiterate previous comments, we have achieved our stated objective on the inventory reduction program effective this first part of May, two months ahead of schedule.
第一季北美營收較前一年同期減少 2,660 萬美元,降幅為 63.3%。銷售下滑主要反映公司庫存狀況,以及降低美國批發商庫存的計畫所帶來的影響。重申先前的說法,我們已於 5 月上旬使庫存削減計畫達成既定目標,比原定時程提前兩個月。
In the first quarter, the European revenues increased by 10.8 million or 24.1% above the same period the previous year, approximately 60% of this increase is due to foreign currency translation, with the rest reflecting solid increased sales highlighted by Spain, Italy, and Poland.
第一季,歐洲營收較去年同期增加1,080萬美元或24.1%;其中約60%的增幅來自外幣換算,其餘則反映銷售穩健成長,主要由西班牙、義大利與波蘭帶動。
Now, for Latin America, in the first quarter of 2003, Latin American revenues decreased to 26.4 million, compared with 29.5 million in 2002.Excluding the negative impact of foreign currency translation of $5.5 million, revenues would have increased 8% from the year ago result.
至於拉丁美洲,2003年第一季拉丁美洲營收降至2,640萬美元,2002年則為2,950萬美元。若排除外幣換算造成的550萬美元負面影響,營收將較去年同期結果成長8%。
And now I'd like to share some highlights from our balance sheet. Cash at March 31, 2003, totaled $309.3 million compared with 245.2 million at year end 2002.We believe that our cash on hand is sufficient to fund our ongoing operations for the foreseeable future.
接下來我想分享資產負債表的一些重點。截至2003年3月31日,現金總額為3.093億美元,較2002年年底的2.452億美元增加。我們相信手上現金足以支應可預見未來的持續營運資金需求。
Accounts receivable declined to 168.3 million at March 31, 2003, from 215.8 million at year end 2002 while in-house inventory remained flat. Stockholders equity increased marginally to 704.9 million at March 31, 2003.
應收帳款截至2003年3月31日降至1.683億美元,較2002年年底的2.158億美元減少,而自有庫存則維持持平。截至2003年3月31日,股東權益小幅增加至7.049億美元。
Now, with that I'd like to turn the call back over to Rob for closing comments. Rob?
那麼,接下來我想把電話會議交回給Rob做結語。Rob?
Robert W. O'Leary - Chairman and CEO
Robert W. O'Leary - Chairman and CEO
Thanks, Bary.
謝謝你,Bary。
Before we open the call up for questions and answer, I'd like to touch on a few areas of particular interest.
在我們開放提問並回答問題之前,我想先談幾個特別值得關注的領域。
We continue to make excellent progress on our divestiture efforts, and in the process, we have improved operations. In fact, for the first time in over a year ago year, we have seen substantial improvement in our Russian operations. We have received well over a dozen bids for our Russian businesses, and most recently reduced the number of bidders to a core group.
我們在資產出售(divestiture)工作上持續取得極佳進展,並在此過程中改善了營運。事實上,這是一年多以來我們首次看到俄羅斯營運出現顯著改善。我們已收到十多份針對俄羅斯業務的投標,並在最近將投標者數量縮減至一個核心群組。
Our biomedical business is farther along in the sales process than our Russian operation. We remain on track to complete all of our planned divestitures by the end of the year. By now our proxy statement and annual report have been distributed to shareholders. You've had a chance to review it and you will have undoubtedly seen the strides we have made in the area of corporate governance. This is something I am particularly proud of as it sets the tone and an expectation for the company to be more accountable to its shareholders.
我們的生物醫學業務在出售流程上比俄羅斯業務更為超前。我們仍按計畫在今年年底前完成所有預定的資產出售。目前我們的委託書說明書(proxy statement)與年報已發送給股東。你們已經有機會審閱,並且無疑已看到我們在公司治理方面所取得的進展。我對此特別自豪,因為這為公司定下基調並建立期待,使公司對股東更具問責性。
We are truly putting the past behind us. By implementing an active governance platform that includes such physician extension steps as the selection of a lead director when the roles of chairman and CEO are held by one individual, as they are now, the ability of independent directors to schedule executive sessions without management attendance, as we will do in May, and the periodic rotation of committee members and formal evaluation of the chairman and chief executive officer.
我們確實正在把過去拋諸腦後。透過推動積極的治理架構,其中包括若干治理延伸措施,例如:當董事長與執行長職務由同一人擔任(如目前情況)時選任首席獨立董事(lead director);獨立董事得以在無管理階層出席下安排執行會議(我們將於5月進行);以及定期輪調委員會成員並對董事長與執行長進行正式評估。
While we have made substantial progress in these first nine months, clearly this is a continuing process and more will be done.
雖然在這前九個月我們已取得重大進展,但顯然這是一個持續的過程,後續還會做得更多。
Lastly, while I hate to talk about the absence of a negative, being a positive, as you may have noticed, or at least I hope you have noticed, in today's earnings release, for the first time in a long time, we did not record or report any one-time charges in the quarter.
最後,雖然我不太喜歡把「沒有負面」當作「正面」來談,但如你們可能已注意到——至少我希望你們注意到了——在今天的盈餘新聞稿中,我們很久以來第一次在本季沒有認列或報告任何一次性費用。
I want to thank you all for your continued support of the company. Additionally, I want to thank our employees worldwide who continually perform beyond expectation. Before we open for questions, I'd like to return to Gregg Keever for an important reminder. Gregg?
我要感謝各位持續支持本公司。此外,我也要感謝我們全球員工,他們持續展現超出預期的表現。在我們開放提問之前,我想請Gregg Keever回來做一個重要提醒。Gregg?
Gregory Keever - Executive VP, General Counsel and Secretary
Gregory Keever - Executive VP, General Counsel and Secretary
Thank you, Rob.
謝謝你,Rob。
ICN, as other companies is evaluating with how to comply with the new rules under regulation G and its related regulatory requirements. Ending further clarification of these requirements, the company is not releasing certain information at this time which may have been provided in the past. All appropriate GAAP information will be reported in the company's form 10 Q which will be filed by May 15th.
ICN與其他公司一樣,正在評估如何遵循G規則(Regulation G)下的新規定及其相關監管要求。在等待對這些要求進一步釐清期間,公司目前不會發布某些資訊,而這些資訊過去可能曾提供。所有適當的GAAP資訊將在公司的Form 10-Q中揭露,該文件將於5月15日前提交。
With that, I'd now like to open the call for questions.
那麼,現在我想開放電話會議進行提問。
Operator
Operator
At this time, if you would like to ask a question, please press star, then the number one on your telephone key pad. Again, please limit yourself to one question at a time as we would like to give everyone a chance to ask a question. We'll pause for just a moment to compile the Q and A roster.
此時若您想提問,請在電話鍵盤上按星號(*),再按數字1。再次提醒,請一次只提一個問題,因為我們希望讓每位與會者都有機會提問。我們將暫停片刻以彙整問答名單。
Your first question comes from Michael Tong with Wachovia.
第一個問題來自Wachovia的Michael Tong。
Michael Tong - Analyst
Michael Tong - Analyst
I have a quick question. I was wondering, Rob, if you would confirm for us your royalty as well as EPS expectations for '03.
我有個簡短問題。Rob,我想請你為我們確認一下你們在2003年的權利金以及每股盈餘(EPS)預期。
Robert W. O'Leary - Chairman and CEO
Robert W. O'Leary - Chairman and CEO
Bary?
Bary?
Bary G. Bailey - Executive VP, CFO
Bary G. Bailey - Executive VP, CFO
Yes. At this time we do not have any other information, Michael, that would cause us to change our assumptions that we provided in the fire prior -- for the year end when we provided guidance.
是的。Michael,目前我們沒有任何其他資訊會讓我們改變先前——也就是在年終提供財測指引時——所提出的假設。
Michael Tong - Analyst
Michael Tong - Analyst
Thank you.
謝謝。
Operator
Operator
Your next question comes from Eric Miller (ph) with Heartland Advisors.
下一個問題來自Heartland Advisors的Eric Miller(音)。
Eric Miller - Analyst
Eric Miller - Analyst
Have you disclosed of what you think in ranges of the proceeds that you want to get for Russia in the biomedical?
你們是否揭露過,對於俄羅斯與生物醫學業務,你們希望取得的出售款項大概落在什麼區間?
Gregory Keever - Executive VP, General Counsel and Secretary
Gregory Keever - Executive VP, General Counsel and Secretary
Eric, we have not. Bary, anything to supplement?
Eric,我們沒有。Bary,有什麼補充嗎?
Bary G. Bailey - Executive VP, CFO
Bary G. Bailey - Executive VP, CFO
The only thing, Eric, I would point out is that as we looked at our discontinued operations, we are obviously make judgments as to the fair value of those and reflect that in our balance sheet as discontinued operations.
Eric,我唯一想指出的是,當我們檢視已終止營運時,我們顯然會就其公允價值作出判斷,並在資產負債表中以已終止營運反映。
Eric Miller - Analyst
Eric Miller - Analyst
Okay, thanks.
好的,謝謝。
Operator
Operator
Your next question comes from David Home (ph) with Advent Capital.
下一個問題來自Advent Capital的David Home(音)。
David Home - Analyst
David Home - Analyst
Good morning. Can you tell me what cash flow from operations was in the OC or capital expenditures?
早安。你能告訴我營運活動現金流(OC)或資本支出是多少嗎?
Bary G. Bailey - Executive VP, CFO
Bary G. Bailey - Executive VP, CFO
David, this is Bary Bailey again. Because of the requirements under RegG we would have to break out the various elements of cash flow and because that's not available, we can't present that at this time, it will be available in the queue.
David,我是Bary Bailey。由於Reg G的要求,我們必須把現金流的各個要素拆分揭露;因為目前無法提供這些資料,所以我們現在不能呈現,之後會在10-Q裡提供。
David Home - Analyst
David Home - Analyst
Right. Was it positive?
了解。那是正的嗎?
Bary G. Bailey - Executive VP, CFO
Bary G. Bailey - Executive VP, CFO
Yes.
是的。
David Home - Analyst
David Home - Analyst
'Cause I note that -- I think you had -- your core trend cash of 309 million, 95 million of that is at Ribopharm.
因為我注意到——我想你們的——核心趨勢現金是3.09億美元,其中9,500萬美元是在Ribopharm。
Bary G. Bailey - Executive VP, CFO
Bary G. Bailey - Executive VP, CFO
David, I'm getting the high sign here if we wanted to limit this to one question, if I could move that to the back of the queue, if you will, for additional questions, just want to be fair to everybody.
David,我這邊收到提示希望每次只問一個問題;為了對大家公平,如果可以的話,我想把這個問題放到問答名單後面,等你之後再追加提問。
Operator
Operator
Your next question comes from Jeff Molden (ph) with Caleford (ph) Capital.
下一個問題來自Caleford(音)Capital的Jeff Molden(音)。
Jeff Molden - Analyst
Jeff Molden - Analyst
Hi. I was referring reviewing the profitability of the business back in the late '90s, before you had a meaningful royalty revenue extreme and I calculate something in the mid teens consistently, 16, 17 -
嗨。我在回顧1990年代末期該業務的獲利能力,當時你們還沒有顯著的權利金收入來源,我計算出來大致都穩定在十幾個百分點的中段,大約16、17——
Gregory Keever - Executive VP, General Counsel and Secretary
Gregory Keever - Executive VP, General Counsel and Secretary
Excuse me, but you're fading out. We're having trouble hearing you talk.
不好意思,你的聲音變小了。我們聽你說話有點困難。
Jeff Molden - Analyst
Jeff Molden - Analyst
I was looking at the profit margins of the business back in the late '90s basically before you started reporting a revenue stream from the royalty business. And I was curious, based on where your business or the mix of the business is going forward excluding Ribapharm, can you talk about where you would like to see your operating margins once your restructuring is complete?
我在看貴公司在 90 年代末期的業務利潤率,基本上是在你們開始從權利金業務申報收入來源之前。我很好奇,基於未來貴公司業務或業務組合的走向(不含 Ribapharm),能否談談在重整完成後,你們希望營業利潤率達到什麼水準?
Timothy C. Tyson - President and COO
Timothy C. Tyson - President and COO
Tim Tyson.
Tim Tyson。
We expect the operating margins to improve. We are looking at the opportunities to reduce cost in areas that aren't adding value to the business and investing in other areas, and part is in the earnings area. And we expect to more closely reflect that of the industry, of specialty pharma.
我們預期營業利潤率會改善。我們正在尋找機會,在那些對業務不增值的領域降低成本,並在其他領域加大投資,其中一部分也會反映在獲利表現上。我們預期會更接近專科製藥(specialty pharma)產業的水準。
Jeff Molden - Analyst
Jeff Molden - Analyst
I'm not a specialty farm analyst. Can you give me some kind of guideline what that means?
我不是專科製藥的分析師。你能給我一些指引,說明那代表什麼嗎?
Timothy C. Tyson - President and COO
Timothy C. Tyson - President and COO
We're -- we're probably approaching the -- in operating income are you saying or which margin position are you talking? Jeff?
我們——我們可能接近——你是指營業利益率嗎,還是你在談哪一種利潤率水準?Jeff?
Operator
Operator
Your next question comes from Bart Epker (ph).
下一個問題來自 Bart Epker(音) 。
Timothy C. Tyson - President and COO
Timothy C. Tyson - President and COO
I'll catch that up, Jeff, with you, I'm not sure which margin you were talking about.
Jeff,我之後再跟你補上,我不確定你剛剛指的是哪一種利潤率。
Gregory Keever - Executive VP, General Counsel and Secretary
Gregory Keever - Executive VP, General Counsel and Secretary
Jeff, when you get a chance, Jeff, please come back in for another question. Excuse me, who's next?
Jeff,等你有機會的時候,Jeff,請再回來問下一個問題。不好意思,下一位是誰?
Operator
Operator
Your next question comes from Bart Epker with Par Capital Management.
下一個問題來自 Par Capital Management 的 Bart Epker。
Bart Epker - Analyst
Bart Epker - Analyst
Hi. Can you refresh me on the dollar amount of the inventory work-down and was that completed by March 31st or as of today?
嗨。你能幫我回顧一下庫存去化(inventory work-down)的金額是多少嗎?以及這是在 3 月 31 日前就完成了,還是截至今天才完成?
Bary G. Bailey - Executive VP, CFO
Bary G. Bailey - Executive VP, CFO
Bart, this is Bary Bailey. I don't think we ever communicated a dollar amount. We indicated that we had a significant reduction by year end, and we've completed the overall inventory impact which I believe from the last quarter we indicated was over 10 months of supply. We completed that effective the end of April.
Bart,我是 Bary Bailey。我想我們從未對外溝通過一個具體金額。我們表示在年底前已大幅降低,而我們已完成整體庫存影響的處理;我記得在上一季我們提到那相當於超過 10 個月的供應量。我們在 4 月底已完成。
Bart Epker - Analyst
Bart Epker - Analyst
Thank you.
謝謝。
Operator
Operator
In order to ask a question, please press star one. We do have a question from Jeff Molden with Caleford Capital.
若要提問,請按星號一。我們有一個問題來自 Caleford Capital 的 Jeff Molden。
Jeff Molden - Analyst
Jeff Molden - Analyst
Hi again. I was thinking after corporate expenses your operating profit of 12 six in pharmaceuticals this quarter was a little below corporate expenses of 13 eight and I compare that operating loss, if you will, to let's say a 16 1/2% margin in 1997 after corporate expenses. That's a different business, I understand. But I'm wondering if that represents a reasonable target for your future operations let's say a couple of years from now, excluding royalties.
再次你好。我在想,扣除公司費用後,本季你們製藥業務的營業利益 12.6(百萬)略低於公司費用 13.8(百萬);我把那個營業虧損(如果你願意這麼稱呼)拿來對比 1997 年扣除公司費用後約 16.5% 的利潤率。我理解那是不同的業務。但我想知道,若不含權利金,這是否能作為你們未來營運(例如兩年後)的合理目標?
Bary G. Bailey - Executive VP, CFO
Bary G. Bailey - Executive VP, CFO
Jeff, this is Bary. Let me -- I suspect you're looking at Table 2 on the -- that was attached to the earnings release. While I -- we haven't really set out, other than some relative percentage on gross margin, we've anticipated as we grow in the future, you'll notice that North America is down significantly compared to last year. I think that's driving a lot of your assessment.
Jeff,我是 Bary。讓我——我猜你是在看隨財報新聞稿附上的表 2。雖然我們除了對毛利率的一些相對百分比之外,並沒有真正設定明確目標,但我們預期隨著未來成長,你會注意到北美相較去年大幅下滑。我想那是你評估的主要驅動因素。
Jeff Molden - Analyst
Jeff Molden - Analyst
That's true. But I'm just wondering if it's possible to share any kind of target for operations in the future.
沒錯。但我只是想知道,是否可能分享任何關於未來營運的目標?
Bary G. Bailey - Executive VP, CFO
Bary G. Bailey - Executive VP, CFO
I think that, Jeff, our targets are to get back in the ranges that you were looking at there and to be greater than 15%15%.
我認為,Jeff,我們的目標是回到你剛剛看到的那個區間,並且要高於 15%——15%。
Jeff Molden - Analyst
Jeff Molden - Analyst
Thank you very much.
非常感謝。
Gregory Keever - Executive VP, General Counsel and Secretary
Gregory Keever - Executive VP, General Counsel and Secretary
Jeff, obviously, you know, there's been a -- in the last couple of quarterly calls, there's been a lot of speculation that with any profit in the specialty farm that business at all. As I think you can see with this quarter's results, even without much help from North America, where our most attractive market and where we're putting most of our focus, the potential for the specialty farm that business is beginning to become self-evident. I think the -- the only real question is just how good can we make it.
Jeff,顯然你知道,在最近幾次季度電話會議中,外界一直有很多揣測,認為專科製藥那塊業務是否能有任何獲利。如你從本季結果所見,即使北美沒有太多助力——而北美是我們最具吸引力的市場,也是我們投入最多心力的地方——專科製藥業務的潛力正開始變得不言自明。我想——唯一真正的問題只是,我們能把它做到多好。
Operator
Operator
Your next question comes from Matt Triplet (ph) with Quaker Capital Management.
下一個問題來自 Quaker Capital Management 的 Matt Triplet(音)。
Matt Triplet - Analyst
Matt Triplet - Analyst
I'm wondering if based on IMS data if you can attempt to size what you think end market sales of your North American products were for this quarter since obviously sales and wholesalers did not reflect that.
我想知道,根據 IMS 數據,你們是否能嘗試估算本季你們北美產品的終端市場銷售額大概是多少,因為顯然你們對批發商的銷售並未反映那個數字。
Bary G. Bailey - Executive VP, CFO
Bary G. Bailey - Executive VP, CFO
Matt, this is Bary. We have, obviously, for a number of products, IMS data but we don't have it in a format that would make us present over there because we can talk about units and this that you all have access to but we can't carve out product by product under Reg-G.
Matt,我是 Bary。我們當然對多項產品有 IMS 數據,但我們沒有以一種適合在這裡呈現的格式整理;因為我們可以談論你們也能取得的單位數等資訊,但在 Reg-G 的規範下,我們不能逐一按產品拆分。
Matt Triplet - Analyst
Matt Triplet - Analyst
Let me ask the question a different way. Previously you said your expectation or thought was you were losing 15 million -- or you weren't capturing in your reported results probably the equivalent of 10 to 15 million in sales per quarter, I mean, is that still an accurate number here?
那我換個方式問。你們先前說過,你們的預期或看法是,你們每季大概少了 1,500 萬美元——或者說,你們在已申報的結果中可能沒有反映相當於每季 1,000 萬到 1,500 萬的銷售額;這個數字在這裡仍然準確嗎?
Gregory Keever - Executive VP, General Counsel and Secretary
Gregory Keever - Executive VP, General Counsel and Secretary
As far as 10 to 15 million as a result of what?
你說的 1,000 萬到 1,500 萬是因為什麼原因造成的?
Matt Triplet - Analyst
Matt Triplet - Analyst
The stocking of the wholesalers.
批發商的囤貨(stocking)。
Bary G. Bailey - Executive VP, CFO
Bary G. Bailey - Executive VP, CFO
I don't think we've mentioned an inventory -- a number. We talked about months and we talked about relative percentages captured by the end of the year which left the remaining amount, obviously, for the first four months of this year. Again, I'll reiterate, I think it was over a 10-month supply that we were dealing with. We resolved about 60% of that in the year before, in '02 and the balance came in this year.
我不認為我們提過一個庫存——一個具體數字。我們談的是月數,也談到年底前已回收的相對百分比,這也就留下了顯然在今年前四個月要處理的剩餘部分。我再重申一次,我認為我們面對的是超過 10 個月的供應量。我們在前一年,也就是 2002 年,解決了其中約 60%,其餘的在今年完成。
Gregory Keever - Executive VP, General Counsel and Secretary
Gregory Keever - Executive VP, General Counsel and Secretary
Let me just complement, Bary, the 10 to 15 million dollar number was given earlier before you joined the company. And, you know, that's probably a good ballpark.
我補充一下,Bary,1,000 萬到 1,500 萬美元這個數字是在你加入公司之前更早時候提供的。而且,你知道,那大概是一個不錯的概略區間。
Matt Triplet - Analyst
Matt Triplet - Analyst
Okay. So presumably we should begin to see those sales showing up next quarter, then?
好的。所以推測下季我們應該就會開始看到那些銷售反映出來,對吧?
Gregory Keever - Executive VP, General Counsel and Secretary
Gregory Keever - Executive VP, General Counsel and Secretary
Yes, sir. Well, remember, we won't have a full quarter because we were still de-stocking in -- in April.
是的,先生。不過請記得,我們不會有完整一季,因為我們在 4 月仍在去庫存(de-stocking)。
Matt Triplet - Analyst
Matt Triplet - Analyst
But certainly part of it?
但至少會反映一部分?
Gregory Keever - Executive VP, General Counsel and Secretary
Gregory Keever - Executive VP, General Counsel and Secretary
Oh, absolutely. Absolutely.
喔,當然。當然。
Matt Triplet - Analyst
Matt Triplet - Analyst
Thank you.
謝謝。
Operator
Operator
Your next question comes from Bart Epker with Par Capital Management.
下一個問題來自 Par Capital Management 的 Bart Epker。
Bart Epker - Analyst
Bart Epker - Analyst
Have you come up with a time frame for coming up with the answer on Ribopharm, if you will?
你們是否已經訂出一個時間表,用來得出 Ribopharm 這件事的答案(如果你願意這麼說)?
Gregory Keever - Executive VP, General Counsel and Secretary
Gregory Keever - Executive VP, General Counsel and Secretary
At the present time, we have not come up with a time frame. There are still a number of significant variables. We -- and we're continuing to analyze and evaluate the circumstances. We, for example, are waiting for the decision on the summary judgment in the generic case. The -- we are going to be very interested to hear the -- what Schering has to say in its concerns earnings call coming up, I believe, on the 13th.And the pretrial conferences for the trial on the merits in the generic is going to be the early first -- I think the 2nd and 4th of June. And that trial is scheduled for the 24th of June. So there are a number of significant events that are coming up. Some or all of which are important to our considerations here and to all of the investors. I can only think now if we had acted precipitously earlier, what people might be thinking of us now, given the development of a number of unforeseen events here over the last five or six months. But there's no decision made at this time. We are actively in the process of evaluating it. And as -- as these things begin to have more texture, we'll be prepared to make a decision and move forward one way or the other. Or in fact to make a decision to do nothing.
目前,我們尚未提出一個時間表。仍然存在若干重大變數。我們——而且我們仍在持續分析並評估相關情況。例如,我們正在等待學名藥案件中簡易判決(summary judgment)的裁定結果。此外——我們也非常關注——我相信在13日即將召開的Schering財報電話會議上,將會如何說明其疑慮。而學名藥實體審理(trial on the merits)的審前會議將在六月上旬的前段——我想是6月2日與4日。而該審理排定於6月24日。因此,接下來將有多項重大事件。其中部分或全部,對我們在此的考量以及所有投資人都很重要。我現在只能想,如果我們先前草率行事,鑑於過去五、六個月出現了多項未預見的事件發展,人們現在可能會如何看待我們。但目前尚未做出任何決定。我們正積極進行評估。而隨著這些事情逐漸更明朗、更具體,我們將準備好做出決定,並以某種方式推進。或者事實上,也可能做出不採取任何行動的決定。
Operator
Operator
Your next question comes from Robert Ull (ph) with Wells Fargo Securities.
下一個問題來自Wells Fargo Securities的Robert Ull(音)。
Robert Ull - Analyst
Robert Ull - Analyst
Thank you and good morning.
謝謝,早安。
Could you just update on the U.S. Pharma business and how it's organized in marketing things such as size of sales force, what they're detailing and which customers they're promoting products to and how that might change going forward?
您能否更新一下美國製藥業務的情況,以及其行銷組織方式,例如銷售團隊規模、他們在拜訪時主要介紹哪些內容、向哪些客戶推廣產品,以及未來可能會如何調整?
Wes Wheeler - President of North America
Wes Wheeler - President of North America
This is Wes Wheeler, I can answer the question around the sales force size. We are primarily a dermatology sales force in the United States. We are contribute constructed a bit differently in other regions but in North America, primarily a dermatology sales force and through the IMS data sources that we have, we're able to -- to target just about all of the really high prescribers in the dermatology business with only 60 sales representatives and they are distributed around the country. We also have a very robust marketing team here in Costa Mesa supported by all the usual functions.
我是Wes Wheeler,我可以回答關於銷售團隊規模的問題。我們在美國主要是一支皮膚科銷售團隊。在其他地區我們的架構略有不同,但在北美,我們主要是皮膚科銷售團隊;透過我們所掌握的IMS資料來源,我們能夠——以僅60名業務代表——鎖定皮膚科領域幾乎所有真正的高處方醫師,他們分布在全國各地。我們在Costa Mesa也有一支非常強健的行銷團隊,並由所有常規職能部門提供支援。
Gregory Keever - Executive VP, General Counsel and Secretary
Gregory Keever - Executive VP, General Counsel and Secretary
I would also say Wes has led a rationalization effort here where we've gone through a very intensive reevaluation of our past sales performance, have basically changed out the bottom one -- one-fourth of that 20% of that sales force and recruited in new, higher performers and we have invested significantly in the last six months in sales training as well as providing newly developed sales training aids.
我也想補充,Wes在此主導了一項合理化(rationalization)工作,我們對過去的銷售表現進行了非常密集的重新評估,基本上汰換了該銷售團隊中表現最差的——約四分之一,也就是約20%——並招募了新的、更高績效的人員;同時在過去六個月,我們也在銷售訓練方面投入了大量資源,並提供新開發的銷售訓練輔助工具。
Bary G. Bailey - Executive VP, CFO
Bary G. Bailey - Executive VP, CFO
We're also just completing a sales force size and structure initiative, looking at how to improve our targeting and reaching the positions that Wes talked about and we'll be adding a few additional sales reps, five to 10, in the next few months.
我們也即將完成一項關於銷售團隊規模與架構的專案,檢視如何改善我們的目標鎖定與觸及Wes所提到的醫師;未來幾個月我們將再增加少數業務代表,大約5到10位。
Gregory Keever - Executive VP, General Counsel and Secretary
Gregory Keever - Executive VP, General Counsel and Secretary
While we are certainly doing this around the world, we are obviously much more intensively pursuing this in North America with the decision to focus much more than in the past the company's effort in the best pharmaceutical market in the world here in North America. So while we've had our inventory reduction efforts intensely under way and very much your focus, as it should be, we have been hard at work continuing to bring -- to do the kind of things that are going to cause pull-through and to allow us to hit the ground at full speed as this reduction -- inventory reduction effort is completed.
雖然我們確實在全球推動這些工作,但顯然在北美我們投入得更為密集,因為公司已決定相較以往更聚焦於北美——也就是全球最佳的藥品市場——來投入公司的資源。因此,儘管我們的去庫存(inventory reduction)工作正如火如荼進行,且也確實是各位關注的重點(也應該如此),我們同時也一直努力推動——做出那些能帶動終端拉動(pull-through)的事情,並讓我們在這波去庫存工作完成後,能以全速起跑。
Operator
Operator
Your next question comes from Elizabeth Jones (ph) with Bank of America Capital Management.
下一個問題來自美國銀行資本管理(Bank of America Capital Management)的Elizabeth Jones(音)。
Elizabeth Jones - Analyst
Elizabeth Jones - Analyst
Yes. Congratulations on a good quarter. And I just wanted to get some -- little bit more detail on Latin America. It came in a little bit below expectations and I just wasn't sure what factors were contributing to that.
是的。恭喜本季表現不錯。我想再多了解一些拉丁美洲的細節。該區表現略低於預期,我不太確定是哪些因素造成的。
Bary G. Bailey - Executive VP, CFO
Bary G. Bailey - Executive VP, CFO
Yes, this is Bary. Again, I wanted to point out that we did have a necessary negative impact as a result of foreign currency translation in the markets. And that had the impact to us. The -- that drove a significant part of it. We did have an 8% increase in sales when you exclude that.
是的,我是Bary。再次說明,我們確實因各市場的外幣換算(foreign currency translation)而受到必要的負面影響。這對我們造成了影響。——這是其中相當重要的一部分原因。若排除該因素,我們的銷售仍成長了8%。
Elizabeth Jones - Analyst
Elizabeth Jones - Analyst
Thank you.
謝謝。
Operator
Operator
Your next question comes from Sina Lunde (ph) with Cafe Financial.
下一個問題來自Cafe Financial的Sina Lunde(音)。
Sina Lunde - Analyst
Sina Lunde - Analyst
Hi, good morning.
嗨,早安。
Back to Ribopharm. I guess your comment's a bit different than what you have been saying in the past. In the past I believe you strongly believed in the patents and stood behind it. But today it sounds like you want to wait and see what happens with the patent issues?
回到Ribopharm。我想你們今天的說法和過去有點不同。過去我記得你們非常相信專利並且堅定支持。但今天聽起來你們想先觀望專利議題會如何發展?
Gregory Keever - Executive VP, General Counsel and Secretary
Gregory Keever - Executive VP, General Counsel and Secretary
Not at all. We still believe strongly in -- in the patents, as evidenced by our guidance. It's just only prudent that we -- that we wait and see the developments of this -- these intermediate events here and the results of what Schering has to say about some of the issues that's been raised about the competitive hepatitis C market. There is no less enthusiasm for the defense of our patents or our belief in our ultimate success. Absolutely none.
完全不是。我們仍然非常相信——相信這些專利,這也反映在我們的財測指引上。只是我們謹慎起見——我們應該等待並觀察這些——這些中間事件的發展,以及Schering將如何就一些已被提出、關於競爭激烈的C型肝炎市場的議題做出說明。我們對捍衛專利的熱忱或對最終勝訴的信念,絲毫沒有減少。絕對沒有。
And for that matter, I would say nothing but continued enthusiasm for the efforts under way at Ribopharm. We have a top-notch management team, an incredible group of dedicated scientists, and we're very excited about what's -- about what's happening there.
同樣地,我也要說,對於Ribopharm目前正在進行的各項努力,我們只有持續的熱忱。我們擁有一流的管理團隊、一群非常優秀且投入的科學家,我們對那裡正在發生的事情——對那裡的進展——感到非常振奮。
Sina Lunde - Analyst
Sina Lunde - Analyst
Can we get those dates again for the - the dates for the trial.
可以再提供一次那些日期嗎——審理的日期。
Gregory Keever - Executive VP, General Counsel and Secretary
Gregory Keever - Executive VP, General Counsel and Secretary
All right, first of all, the summary judgment hearing has already been held on March 31st.We are awaiting the judge's decision. We have not -- she's not handed down a decision. The pretrial conferences, I believe, are the 2nd of June and then the trial itself is has now been scheduled for the 24th of June.
好的,首先,簡易判決聽證會已於3月31日舉行。我們正在等待法官的裁定。我們尚未——她尚未作出裁決。審前會議我相信是6月2日,然後審理本身目前已排定在6月24日。
Sina Lunde - Analyst
Sina Lunde - Analyst
Thank you.
謝謝。
Operator
Operator
Your next question comes from Matt Triplet with Quaker Capital Management.
下一個問題來自Quaker Capital Management的Matt Triplet。
Matt Triplet - Analyst
Matt Triplet - Analyst
I guess a question about the SG and A numbers reported today. Obviously market markedly better than Q4 although not necessarily year over year and I wonder I guess as it relates to that, are last year's SG and A numbers representative? And, you know, where do you see the numbers going from here? Can they come down materially from the current levels?
我想問一下今天公布的SG&A數字。顯然比第四季明顯改善,但未必是年對年改善;就此我想請教,去年的SG&A水準是否具有代表性?以及,你認為接下來這些數字會如何走?是否可能從目前水準實質下降?
Timothy C. Tyson - President and COO
Timothy C. Tyson - President and COO
This is Tim Tyson. I think that we have said that we intend to reach an SG and A level that's significantly lower than the historical average and that we are focusing on this area. It's an area where there's an opportunity, we have not established a fixed number, but expect some significant improvements.
我是Tim Tyson。我想我們已經說過,我們打算把SG&A降到顯著低於歷史平均的水準,而且我們正聚焦在這個領域。這是一個有改善空間的領域;我們尚未設定一個固定數字,但預期會有一些顯著的改善。
Matt Triplet - Analyst
Matt Triplet - Analyst
as it relates to that, I guess you're speaking more in terms of as a percentage of revenues?
就這一點而言,我想你比較是在談以營收百分比來看?
Timothy C. Tyson - President and COO
Timothy C. Tyson - President and COO
Yes, of course.
是的,當然。
Matt Triplet - Analyst
Matt Triplet - Analyst
I guess my question there is, you know, how significant -- is that really a numerator or denominator effect, how much do you have to grow the revenue denominator or is that as even relates to current sales levels?
我想我這裡的問題是,你知道,這到底有多重要——這真的是分子或分母的效果嗎?你必須把作為分母的營收成長多少,或者這是否也與目前的銷售水準有關?
Timothy C. Tyson - President and COO
Timothy C. Tyson - President and COO
It's really both. We're focusing on efficiencies and product test productivities to reduce the actual expenses as well as looking at it over time to reduce them significantly as a percent of sales.
其實兩者都有。我們正專注於效率提升與產品測試的生產力,以降低實際費用,同時也從時間推移的角度來看,將其占銷售額的比重顯著降低。
Matt Triplet - Analyst
Matt Triplet - Analyst
Okay. So there are dollars being spent there now that you don't anticipate spending in the subsequent quarters?
了解。所以現在確實有一些支出,你們預期在後續季度不會再花?
Timothy C. Tyson - President and COO
Timothy C. Tyson - President and COO
Yes.
是的。
Matt Triplet - Analyst
Matt Triplet - Analyst
Okay.
好。
Operator
Operator
Your next question comes from Bart Epker with Par Capital Management.
下一個問題來自 Par Capital Management 的 Bart Epker。
Bart Epker - Analyst
Bart Epker - Analyst
Hi. If I could just go back to Ribopharm for one more minute. It seems to me that there's always going to be kind of court cases and material events just around the corner, and that if -- if we wait for those to decide what we're going to do we all may be old and gray. What -- what's different about the ones that are around the corner this quarter than the ones that are going to be around the corner next quarter and the quarter after that?
嗨。如果我可以再回到 Ribopharm 一分鐘。在我看來,似乎總會有一些訴訟案件和重大事件就在轉角處;如果——如果我們等那些結果出來才決定要做什麼,我們大家可能都會變得又老又白髮。那——這一季轉角處的那些事件,跟下一季、再下一季轉角處的那些事件,有什麼不同?
Gregory Keever - Executive VP, General Counsel and Secretary
Gregory Keever - Executive VP, General Counsel and Secretary
Well, let me just say, Bart, that I promise you we're going to act before -- before you're old and gray. It may be too late for me, but we're not going to let that happen to you. I can tell you that -- I agree with you, there will always be questions and risks in the marketplace and in litigation. But these are specifically known events that will -- that will give us -- they're milestones that will give us some -- some insight into what the -- what the future may hold and I think they're in the relative near term so it's important that we should wait. And we, again, had we acted in imprudently several months earlier, we'd probably be very much scrutinized and criticized for having valued things too highly or too lowly or whatever. And you'll never have perfect and complete information. I think that's wise advice, Bart. But it's prudent to wait and make sure you have the information that can significantly help you to make an intelligent decision.
嗯,我先說,Bart,我向你保證,我們會在——在你變得又老又白髮之前採取行動。對我來說可能已經太晚了,但我們不會讓那發生在你身上。我可以告訴你——我同意你的看法,市場與訴訟中永遠會有問題與風險。但這些是特別明確、已知的事件——它們是一些里程碑,會讓我們對未來可能的走向有一些——一些洞見;而且我認為它們相對在近期內就會發生,所以等待是重要的。而且我們再次強調,如果我們在幾個月前不夠審慎地採取行動,我們很可能會因為估值過高或過低或其他原因而受到嚴格檢視與批評。你永遠不會有完美且完整的資訊。我認為那是很明智的建議,Bart。但謹慎地等待,確保掌握能夠顯著幫助你做出明智決策的資訊,是審慎之舉。
Bart Epker - Analyst
Bart Epker - Analyst
Thank you.
謝謝。
Operator
Operator
Your next question comes from Matt Triplet with Quaker Capital Management.
下一個問題來自 Quaker Capital Management 的 Matt Triplet。
Matt Triplet - Analyst
Matt Triplet - Analyst
Just a question regarding Latin America. Is there a pronounced seasonality to their business, at least relative to Q4?
有個關於拉丁美洲的問題。他們的業務是否有明顯的季節性,至少相對於第四季而言?
Timothy C. Tyson - President and COO
Timothy C. Tyson - President and COO
Tim Tyson. Seasonality. I think the answer is that there's some flux fluctuations in demand. Some of the issues that you see there have to do with the normal pricing issues so we had some -- a price increase at the end of the year and you get some buy-in at the end of the year that works its way through the system over time. And this is a viral market as well as a market where we're selling some significant vitamin -- nutritional complement supplement, the indictable beta ecta (ph) and so there are some seasonalities (ph).
Tim Tyson。季節性。我想答案是需求確實有一些起伏波動。你在那裡看到的一些情況與一般的定價因素有關,所以我們在年底做了一次——一次調價,而年底會出現一些提前採購,之後會隨時間在系統中逐步消化。此外,這既是抗病毒市場,也是我們銷售一些重要維生素——營養補充品的市場,例如所謂的 indictable beta ecta(音),因此確實存在一些季節性(音)。
Matt Triplet - Analyst
Matt Triplet - Analyst
Thank you.
謝謝。
Operator
Operator
Your next question comings from Michael Tong from Wachovia.
下一個問題來自 Wachovia 的 Michael Tong。
Michael Tong - Analyst
Michael Tong - Analyst
Hi. I was wondering if you can quantify the operation -- operating income impact based on foreign currency in Europe and in Latin America.
嗨。我想請問你是否可以量化外幣因素在歐洲與拉丁美洲對營運——營業利益的影響。
Bary G. Bailey - Executive VP, CFO
Bary G. Bailey - Executive VP, CFO
Michael, the impact in Latin America is about -- let's see, hold on. A little under half of impact due to foreign currency translations with the balance representing sales. That's a little over a million dollars decrease in operating income. In Europe, it represents about a million increase, or positive impact of foreign currency translation a little north of that. The rest is obviously due to sales.
Michael,拉丁美洲的影響大約是——讓我看看,稍等。由外幣換算造成的影響略低於一半,其餘則代表銷售因素。這使營業利益減少略高於 100 萬美元。在歐洲方面,外幣換算帶來約 100 萬美元的增加,或略高於此的正面影響。其餘顯然是由銷售所致。
Michael Tong - Analyst
Michael Tong - Analyst
Okay. Great. Thanks.
好的。很好。謝謝。
Operator
Operator
At this time there are no further questions. I will now turn the call back to Mr. O'Leary for closing remarks.
目前沒有其他問題。我現在把電話交回給 O'Leary 先生作結語。
Robert W. O'Leary - Chairman and CEO
Robert W. O'Leary - Chairman and CEO
Thank you very much.
非常感謝。
And thank you all for your questions and your times this morning. I -- while I have a few prepared closing remarks, I just want to tell you that this is a watershed event, we believe, for the new management team. This gets us -- this quarter gets us over the hump. And off and running in terms of particularly our focus here in North America on getting the past behind us and getting on with seeing the fruits of our labor in North America.
也感謝各位今天早上提出的問題與撥冗參與。我——雖然我準備了幾點結語,但我想先告訴各位,我們相信這對新的管理團隊而言是一個分水嶺事件。這一季讓我們——讓我們跨過一道關卡。並且開始加速前進,特別是在北美這裡,我們專注於把過去拋在身後,並在北美看到我們努力的成果。
We also continue to be quite -- quite bullish on what's happening in Europe with our efforts there. We have a few more -- a few more slots to fill in our management team, but this group is largely in place and really behaving quite impressively. So our very warm thanks to all of you who have patiently waited for more optimistic words from us. Now it's up to us to deliver the performance.
我們也持續對歐洲那邊的進展保持相當——相當樂觀。我們的管理團隊還有幾個——幾個職缺要補,但這個團隊大致已到位,而且表現確實令人印象深刻。因此,我們非常誠摯地感謝各位一直耐心等待我們說出更樂觀的話。現在就看我們能否交出績效。
I want to close the call by repeating how pleased we are with this progress. One of the greatest accomplishments this quarter has been the building of this management team that has the ability, we believe, to deliver tangible results quarter after quarter. We believe the important thing for you and for us is predictability and consistency. We have more to do on the question of transparency. We take that seriously and we'll be working on it.
我想以再次強調我們對這些進展感到非常滿意來結束本次電話會議。本季最大的成就之一,就是建立了這個管理團隊;我們相信他們有能力在一季又一季交出具體成果。我們認為,對你們與對我們而言,最重要的是可預測性與一致性。在透明度方面我們還有更多工作要做。我們非常重視,並將持續推動。
The team we now have in place brings modern pharmaceutical and healthcare experience along with strong backgrounds in sales and marketing, global manufacturing, supply chain management, and procurement. We believe they will complement our executive team's efforts to guide ICN through its strategic restructuring and the plans for the future. I thank you all for your support and your patience. Good morning.
我們目前到位的團隊帶來了現代製藥與醫療保健的經驗,並具備銷售與行銷、全球製造、供應鏈管理與採購等領域的深厚背景。我們相信,他們將能補強我們高階主管團隊的努力,引導 ICN 完成策略性重整,以及未來的規劃。感謝各位的支持與耐心。早安。
Operator
Operator
This concludes today's ICN first quarter 2003 conference call. Thank you for your participation. At this time you may now disconnect from the conference
今天的 ICN 2003 年第一季電話會議到此結束。感謝各位的參與。此刻您可以掛斷電話,離開會議。